Resource Type

Journal Article 1

Year

2023 1

Keywords

benzydamine 1

cyclin-dependent kinase 2 1

esophageal squamous cell carcinoma 1

patient-derived xenograft 1

Search scope:

排序： Display mode:

Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 290-303 doi: 10.1007/s11684-022-0956-8

Abstract: Here, we found benzydamine, a locally acting non-steroidal anti-inflammatory drug, had potent cytotoxicBenzydamine could suppress ESCC proliferation in vivo and in vitro.In terms of mechanism, CDK2 was identified as a target of benzydamine by molecular docking, pull-downSpecifically, benzydamine inhibited the growth of ESCC cells by inhibiting CDK2 activity and affectingOur study illustrates that benzydamine inhibits the growth of ESCC cells by downregulating the CDK2 pathway

Keywords： benzydamine     cyclin-dependent kinase 2     patient-derived xenograft     esophageal squamous cell carcinoma    

HTML PDF Collect

Title Author Date Type Operation

Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma

Journal Article